Considering the extended dosing interval and prolonged duration of action associated with insulin efsitora, there is potential for concerns regarding prolonged hypoglycemia, delayed recovery from hypoglycemic episodes, and recurrent hypoglycemia. This evidence concerns the gene INS and Hypoglycemia.